Our investors

In April 2021, Adcendo ApS closed a series A investment round at 51m EUR, through an international syndicate of leading life science and biotech investors. The round was extended in April 2023, where an additional 31m EUR was added, and the syndicate was further expanded. A second extension took place in April 2024, further adding 16m EUR and an additional investor, taking total funds raised through our series A and extensions to 98m EUR.

Novo Holdings

Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life sciences investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets

Visit www.novoholdings.dk

RA Capital Management

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization

Visit www.racap.com

Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor with $1.8 billion under management across two fund strategies: Venture & Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States). The Venture & Growth fund of Gilde Healthcare invests in innovative companies active in (Bio)Pharmaceuticals, HealthTech and MedTech. The portfolio of the Venture & Growth fund is balanced with fast growing life science companies from Europe and North America

Visit www.gildehealthcare.com

Ysios Capital

Ysios Capital, a leading Spanish venture capital firm, provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages over USD 420M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies

Visit www.ysioscapital.com


HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe. Since the start in 1996, HealthCap has backed and built more than 100 companies. HealthCap’s investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies which have the potential to be transformative and improve the lives of patients suffering from these conditions

Visit www.healthcap.eu

Pontifax Venture Capital

Founded in 2004, Pontifax is a healthcare-dedicated venture capital firm with $1.2 billion under management. We seek transformative, cutting-edge life sciences technologies at all development stages. Our portfolio comprises of about 100 companies that develop breakthrough solutions to substantial unmet needs.

Visit www.pontifax.com